David Williams, MD
Nephrology · Norman, OKNPI 1518991264
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Otsuka America Pharmaceutical, Inc. accounts for 64.3% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $4,416 and has fallen 85.8% since, to $625 in 2025.
Across 118 payments — averaging $53.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$4K
- AstraZeneca$702
- Amgen$373
- Bayer$247
- Travere Therapeutics, Inc.$202
- Otsuka Pharmaceutical Development & Commercialization, Inc.$126
- plus $619 from 15 others
What the payments were for
- Consulting fees$3,75359%
- Food & beverage$2,46339%
- Education$1362%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $4,083 |
| AstraZeneca | 24 | $702 |
| Amgen(2 entities) | 29 | $373 |
| Bayer | 14 | $247 |
| Travere Therapeutics, Inc. | 7 | $202 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $126 |
| Impulse Dynamics (USA) Inc. | 4 | $119 |
| Akebia Therapeutics Inc | 4 | $62 |
| Ardelyx, Inc. | 3 | $56 |
| Novo Nordisk | 2 | $55 |
| Cormedix Inc. | 2 | $54 |
| Pharmacosmos Therapeutics Inc. | 2 | $45 |
| Baxter Healthcare | 1 | $44 |
| Lilly USA, LLC | 2 | $40 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| GSK | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,352 in reported general payments places this provider in the 80th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 51 | $63,417 |
| ProcritEpoetin Alfa | 11 | $46,095 |
| KerendiaFinerenone | 22 | $26,960 |
| Sevelamer Carbonate | 34 | $21,304 |
| MyrbetriqMirabegron | 11 | $8,947 |
| Torsemide | 73 | $2,367 |
| Febuxostat | 18 | $2,216 |
| Potassium Chloride | 40 | $1,133 |
| Minoxidil | 23 | $993 |
| Hydralazine Hcl | 37 | $988 |
| Amlodipine Besylate | 86 | $843 |
| Metolazone | 35 | $719 |
| Calcitriol | 35 | $658 |
| Metoprolol Succinate | 28 | $608 |
| Carvedilol | 41 | $456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $702 | $63,41751 claims |
| BayerKerendia | $247 | $26,96022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 nephrology providers in Oklahoma.
Other nephrology in Norman
- Cuong NguyenNorman$2K
- Kendral KnightNorman$2K
- Celeste BoeckmanOklahoma City$90K
- Joseph GhataOklahoma City$45K
- Sunil AgrawalTulsa$40K
- Benjamin CowleyOklahoma City$36K
- Pranay KathuriaTulsa$21K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Brad CarterOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.